SHAREHOLDERS’ EQUITY (Details Narrative) - USD ($)			1 Months Ended					3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2024	Aug. 01, 2023	Oct. 31, 2024	Aug. 31, 2023	Feb. 28, 2023	Jul. 31, 2022	Apr. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Jun. 12, 2024	Apr. 04, 2022	Apr. 30, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Payment in cash									$ 3,089,645
Options to acquire shares
Number of shares issued, value								$ (75,000)		$ 1,033,761
Share-based compensation expense											$ 3,240,362	$ 2,582,163
Restricted Stock Units (RSUs) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based compensation expense								1,025,430	$ 857,526		3,240,361	$ 2,582,163
Unrecognized share-based compensation expense	$ 5,403,255							5,403,255			$ 5,403,255
Unrecognized share-based compensation expense period for recognition											8 months 12 days
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accredited investors shares									73,809
Payment in cash									$ 74
Sale of stock										26,143
Number of shares issued, value										$ 26
Precision Healing Merger Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cash consideration							$ 125,966
Payment in cash							$ 600,000
Share price							$ 27.13								$ 30.75	$ 27.13
Options to acquire shares							144,191
Weighted exercise price							$ 10.71
Payment of contingent consideration							$ 10,000,000.0
Precision Healing Merger Agreement [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase shares							4,424
Exercise price							$ 7.32
Expiration date							Apr. 22, 2031
Precision Healing Merger Agreement [Member] | Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase shares							12,301
Exercise price							$ 12.05
Expiration date							Aug. 10, 2030
Precision Healing Merger Agreement [Member] | Accredited Investors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accredited investors shares							165,738
Scendia Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Purchase price						$ 7,600,000
Cash						$ 1,600,000
Equity Shares						291,686
Number of shares withheld						94,798
Cash consideration						$ 10,000,000.0
Number of shares						486,145
Earnout payment				$ 693,000
Scendia Purchase Agreement [Member] | Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Earnout payment			$ 1,100,000
Sales Agreement [Member] | Cantor Fitzgerald & Co [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Percentage of commissions payable to sales agent					3.00%
Sales Agreement [Member] | Cantor Fitzgerald & Co [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sale of stock, consideration received on transaction					$ 75,000,000
Sales Agreement [Member] | Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sale of stock													26,143
Number of shares issued, value													$ 1,100,000
Net proceeds													$ 900,000
Applied Asset Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cash consideration		$ 16,792,037
Payment of contingent consideration		893,000
Purchase price		$ 15,250,000
Equity Shares		73,809
2024 Omnibus Long-Term Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Maximum number of shares available for grant														1,000,000
Number of shares issued	745,085
Number of shares available for issuance	1,000,000							1,000,000			1,000,000
2024 Omnibus Long-Term Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Restricted stock awards granted and issued											164,588
Restricted stock awards granted and issued, fair value											$ 5,765,952